Chapter
The Rise of Psychedelic Psychiatry
12:40 - 25:28 (12:47)
The FDA granted breakthrough therapy status to MDMA in 2017, allowing the first government-sanctioned research trials on a psychedelic drug and reopening the door to widespread medical research on psychedelic compounds for mental health conditions. Researchers issue a note of caution as the long-term impacts of these drugs are still unknown.
Clips
The FDA granting breakthrough therapy status to MDMA allowed for the first government-sanctioned psychedelic research trials.
12:40 - 18:50 (06:10)
Summary
The FDA granting breakthrough therapy status to MDMA allowed for the first government-sanctioned psychedelic research trials. However, it is still early to fully understand the long-term effects of using these compounds for mental health treatment.
ChapterThe Rise of Psychedelic Psychiatry
EpisodeThe Veterans Fighting to Legalize Psychedelics
PodcastThe Daily
Veterans who have experienced the healing benefits of psychedelic therapy are advocating for wider access to these drugs for other veterans, through the creation of advocacy groups and pushing for more research programs and opportunities for therapy.
18:50 - 25:28 (06:37)
Summary
Veterans who have experienced the healing benefits of psychedelic therapy are advocating for wider access to these drugs for other veterans, through the creation of advocacy groups and pushing for more research programs and opportunities for therapy.